Intervention Protocol

You have free access to this content

Interventions for chronic non-hypovolaemic hypotonic hyponatraemia

  1. Evi V Nagler1,2,*,
  2. Maria C Haller2,3,
  3. Wim Van Biesen1,4,
  4. Raymond Vanholder1,2,
  5. Jonathan C Craig5,6,
  6. Angela C Webster5,6,7

Editorial Group: Cochrane Kidney and Transplant Group

Published Online: 25 FEB 2014

DOI: 10.1002/14651858.CD010965

How to Cite

Nagler EV, Haller MC, Van Biesen W, Vanholder R, Craig JC, Webster AC. Interventions for chronic non-hypovolaemic hypotonic hyponatraemia (Protocol). Cochrane Database of Systematic Reviews 2014, Issue 2. Art. No.: CD010965. DOI: 10.1002/14651858.CD010965.

Author Information

  1. 1

    University Hospital Ghent, Renal Division, Department of Internal Medicine, Ghent, Belgium

  2. 2

    European Renal Best Practice (ERBP), guidance issuing body of the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA), Ghent, Belgium

  3. 3

    Krankenhaus Elisabethinen Linz, Department for Internal Medicine III, Nephrology & Hypertension Diseases, Transplantation Medicine & Rheumatology, Linz, Austria

  4. 4

    guidance issuing body of the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA), European Renal Best Practice (ERBP), Ghent, Belgium

  5. 5

    The University of Sydney, Sydney School of Public Health, Sydney, NSW, Australia

  6. 6

    The Children's Hospital at Westmead, Cochrane Renal Group, Centre for Kidney Research, Westmead, NSW, Australia

  7. 7

    The University of Sydney at Westmead, Centre for Transplant and Renal Research, Westmead Millennium Institute, Westmead, NSW, Australia

*Evi V Nagler, Renal Division, Department of Internal Medicine, University Hospital Ghent, De Pintelaan 185, Ghent, 9000, Belgium.

Publication History

  1. Publication Status: New
  2. Published Online: 25 FEB 2014



Additional references

Adrogue 2000
Adrogue 2012
Arampatzis 2013
  • Arampatzis S, Gaetcke LM, Funk GC, Schwartz C, Mohaupt M, Zimmermann H, et al. Diuretic-induced hyponatremia and osteoporotic fractures in patients admitted to the emergency department. Maturitas 2013;75(1):81-6. [MEDLINE: 23489552]
Ellison 2007
FDA 2012
  • US Food, Drug Administration. FDA briefing document for the Cardiovascular and Renal Drug Advisory (CRDAC) - Drug: Lixivaptan. (accessed 30 January 2014).
Higgins 2003
Higgins 2011
  • Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from
Hoorn 2011
Jaber 2011
  • Jaber BL, Almarzouqi L, Borgi L, Seabra VF, Balk EM, Madias NE. Short-term efficacy and safety of vasopressin receptor antagonists for treatment of hyponatremia. American Journal of Medicine 2011;124(10):977.e1-9. [MEDLINE: 21962320]
Kinsella 2010
  • Kinsella S, Moran S, Sullivan MO, Molloy MG, Eustace JA. Hyponatremia independent of osteoporosis is associated with fracture occurrence. Clinical Journal of The American Society of Nephrology: CJASN 2010;5(2):275-80. [MEDLINE: 20056759]
Lindner 2012
Renneboog 2006
  • Renneboog B, Musch W, Vandemergel X, Manto MU, Decaux G. Mild chronic hyponatremia is associated with falls, unsteadiness and attention deficits. American Journal of Medicine 2006;119(71):e1-8. [MEDLINE: 16431193]
Reynolds 2006
Rozen-Zvi 2010
  • Rozen-Zvi B, Yahav D, Gheorghiade M, Korzets A, Leibovici L, Gafter U. Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis. American Journal of Kidney Diseases 2010;56(2):325-37. [MEDLINE: 20538391]
Upadhyay 2009
Verbalis 2007
Verbalis 2010
Wald 2010